Drugs / EG-COVID-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05188469 | Mar 2022 → May 2024 | — | EyeGene Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EG-COVID-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05188469 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA 200μg” NCT05188469 ↗ |
| Route | Intramuscular | “Route of administration: Intramuscular injection” NCT05188469 ↗ |